Ellipses Pharma Considers London Listing

Ellipses Pharma is exploring a London listing via a reverse takeover with Wolfram Resources. The British cancer drug developer targets a valuation up to £500 million and aims to complete the deal by early 2027.

Xurve View
Insights:
A worker walks near an LSEG (London Stock Exchange Group) branded cube inside the LSEG headquarters in Paternoster Square, London, Britain, September 8, 2026. REUTERS/Toby Melville/File Photo

Ellipses Pharma is exploring a London public listing through a reverse takeover with shell company Wolfram Resources, targeting a valuation of up to £500 million ($660 million). The potential floatation provides a welcome boost to the United Kingdom, which has faced an exodus of firms seeking higher valuations in the United States. Founder and chair Chris Evans said the transaction will allow the cancer drug developer to raise capital from public market investors.